Early onset, multiple, bilateral fibroadenomas of the breast: a case report

Cecilia J. Im1*, Ashlie Miller2, Ronald Balassanian3 and Rita A. Mukhtar4

Abstract

Background: While fibroadenomas are common in the general population, affecting 10–20% of women, they are rarely early-onset, multiple, and bilateral.

Case presentation: An 18-year-old woman presented with a 6 year history of multiple, bilateral breast masses without family history of breast disease. Magnetic resonance imaging (MRI, Fig. 1) of the breasts showed innumerable, bilateral breast masses ranging in size from 0.5 to 4 cm. Two needle biopsies showed fibroadenoma. Although the patient’s family history did not meet National Comprehensive Cancer Network (NCCN) guidelines for genetic testing, it was performed due to the rarity of her presentation. Genetic testing identified a pathogenic mutation in the phosphatase and tensin homolog (PTEN) gene.

Conclusions: A germline mutation in PTEN is associated with an increased risk of breast cancer and often occurs as part of Cowden Syndrome. This case highlights the importance of genetic testing in patients with unusual presentations of early-onset, bilateral, and multiple (greater than four) fibroadenomas.

Keywords: PTEN, Fibroadenoma, Genetic testing, Case report

Background

The PTEN protein acts as an antagonist to the P13k/Akt pathway. Insufficient suppression in the setting of a PTEN mutation leads to increased cell proliferation with decreased apoptosis [1]. PTEN hamartoma tumor syndrome is a family of clinical syndromes characterized by germline mutations in the PTEN gene [2]. The best characterized of these is Cowden Syndrome which is associated with increased lifetime cumulative risk of developing cancer in the breast (67–85%), thyroid (35%), kidney (33%), and endometrium (28%) [3]. Additionally, benign breast disease is common in Cowden syndrome, with fibroadenomas found in approximately 35% of PTEN mutation carriers. These fibroadenomas are more likely to be complex and hyalinize at an early age [4].

While fibroadenomas are common in the general population, affecting 10–20% of women, they are rarely multiple and bilateral [5]. Among women with fibroadenomas, only 15% have 2–4 masses in one breast and only 11% have bilateral masses [6]. Additionally, fibroadenomas in adolescents are rare, found in just 0.5 to 4% of patients [7]. The reported data regarding women with bilateral and multiple fibroadenomas is currently limited to less than 20 case reviews without genetic data. Only one other case report characterizes an adolescent with bilateral and more than 4 masses but this study lacks genetic data [8].

Current NCCN guidelines state that major criteria for genetic testing for PTEN hamartoma tumor syndrome include breast, endometrial, or follicular thyroid cancer, multiple gastrointestinal hamartomas, macrocephaly, and the presence of mucocutaneous lesions including trichilemmoma, palmoplantar keratoses, or extensive oral mucosal papillomatosis [9]. This case report provides...
evidence for obtaining germline genetic testing in patients with unusual presentations of fibroadenomas.

Case presentation
An 18-year-old woman presented with multiple, bilateral breast masses with cyclical discomfort associated with her menses. The first mass developed at age 12 near menarche, with several more masses developing and increasing in size over time. She was otherwise healthy, and family history was notable for nasopharyngeal cancer in her paternal grandfather and brain cancer in a paternal cousin who died at age 6 (Fig. 1).

On physical examination, the breast tissue was nearly replaced by multiple smooth, mobile, non-tender, well circumscribed nodules each measuring 1–2 cm in size, with a 4 cm mass in the outer right breast. She had no lymphadenopathy, trichilemmomas, oral papillomatosis, or acral keratosis. There was keratosis pilaris of the upper arms.

Magnetic resonance imaging of the breasts (Fig. 2) showed innumerable, bilateral breast masses ranging in size from 0.5 to 4 cm, and two fine needle biopsies cytomorphology supported a diagnosis of fibroadenoma (Fig. 3). Alternative diagnoses including phyllodes tumor were considered but not seen on biopsy. This patient did not meet criteria for testing under NCCN guidelines and suspicion for underlying hereditary cancer risk was low. However, a custom 100 gene hereditary cancer panel was ordered (Supplementary Material), for genes such as ATM, BRCA1, BRCA2, and PTEN due to the rarity of early onset, bilateral, and multiple fibroadenomas with limited family history.

Genetic testing identified a pathogenic mutation in the PTEN gene consistent with PTEN hamartoma tumor syndrome. Subsequent genetic testing of both parents was negative, consistent with a de novo mutation in this patient, which occurs in 11–48% of PTEN mutation carriers [10].

After discussion of management options, including excisional biopsy of the largest mass, observation, high risk screening with breast MRI, or risk reducing bilateral mastectomies, this patient opted for surgical risk reduction with bilateral mastectomies and reconstruction in the near future. This decision was based on the high lifetime risk of breast cancer, difficulty with surveillance due to the presence of innumerable masses, and patient’s symptoms.

Discussion and conclusions
Although solitary fibroadenomas are very common and benign, the presence of multiple, bilateral fibroadenomas in a young patient should raise suspicion for alternative pathology, which can be assessed with genetic testing. Although this is a single case report, this is the first report of genetic testing in this rare presentation of fibroadenomas. Identification of a PTEN mutation allowed for appropriate cancer screening and risk reducing measures for this patient. Further studies are needed to evaluate the utility and cost-effectiveness of...
genetic testing for all patients with numerous and bilateral fibroadenomas. The frequency of genetic mutations in these patients is currently unknown, highlighting the importance of genetic testing in patients with unusual presentations of fibroadenomas.

**Abbreviations**
MRI: Magnetic resonance imaging; NCCN: National Comprehensive Cancer Network; PTEN: Phosphatase and tensin homolog.

**Supplementary Information**
The online version contains supplementary material available at https://doi.org/10.1186/s12905-021-01311-7.

**Acknowledgements**
We would like to thank Dr. Yunn-Yi Chen for lending her expertise.

**Authors’ contributions**
CJI and RAM were involved in manuscript creation, writing, and editing. AM and RB were major contributors to writing and editing. All authors read and approved the manuscript.

**Funding**
The authors have no funding sources to declare.

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article.

**Declarations**

**Ethics approval and consent to participate**
Patient consent was obtained and this report is considered exempt from review by the UCSF Institutional Review Board.

**Consent for publication**
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.

**Competing interests**
The authors declare that they have no competing interests.

**Author details**
1 School of Medicine, University of California San Francisco, San Francisco, CA, USA. 2 Department of Cancer Genetics, University of California San Francisco, San Francisco, CA, USA. 3 Department of Pathology, University of California San Francisco, San Francisco, CA, USA. 4 Department of Surgery, Division of Surgical Oncology, University of California San Francisco, San Francisco, CA, USA.

**Received: 1 December 2020 Accepted: 15 April 2021**
Published online: 21 April 2021

**References**
1. Lee Y-R, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018;19(9):547–62.
2. Bubien V, Bonnet F, Brouste V, Hoppe S, Barouk-Simonet E, David A, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. J Med Genet. 2013;50(4):255–63.
3. Tan MH, Mester JL, Ngeow J, Rhybicki LA, Orloff MS, Eng C. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400–7.
4. Schrager CA, Schneider D, Gruener AC, Tsou HC, Peacocke M. Similarities of cutaneous and breast pathology in Cowden's Syndrome. Exp Dermatol. 1998;7(6):380–90.
5. Panda SK, Patro B, Mishra J, Dora RK, Subudhi BSK. Multiple fibroadenomas in bilateral breasts of a 46-year-old Indian woman—a case report. 2014;5(5):326–8.
6. Onuigbo W. Breast fibroadenoma in teenage females. Turk J Pediatr. 2009;51(4):326–8.
7. Jayasinghe Y, Simmons PS. Fibroadenomas in adolescence. Curr Opin Obstet Gynecol. 2009;21(5):402–6.
8. Kaur N, Saini S, Somasekhar S, Gupta A. Bilateral florid juvenile fibroadenomas of the breast in an adolescent: a rare indication for subcutaneous mastectomy. J Pediatr Adolesc Gynecol. 2015;28(5):e135–7.
9. Network NCC. Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2020). https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf.
10. Mester J, Eng C. Estimate of de novo mutation frequency in probands with PTEN hamartoma tumor syndrome. Genet Med. 2012;14(9):819–22.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.